In 6 years, from 7 million to 7 billion, drug dealers have entered the doctors' circle, and the circle has gone crazy!

Medical Network April 9 News Medical equipment circulation is surging.

The Chinese medicine department with Chinese medicine equipment as its core has continued to perform, while some traditional ones drug Large companies in circulation also speed up the layout of medical equipment, and the enclosure is mad.

Top 10 in the country medicine The circulation company Ruikang Pharmaceutical achieved operating revenue of 23.32 billion yuan in 2017, an increase of 49.3% year-on-year, and a net profit of 1.009 billion yuan, an increase of 70.8% year-on-year. medical instruments The revenue of the sector is about 7 billion yuan, accounting for about 30% of the total revenue.

The circulation of medical equipment, the nation's No. 1 national drug device in 2017 had a revenue of 30.7 billion yuan. There is still a big gap between Rikang Pharmaceutical and China National Medical Devices Co., Ltd. However, Sinopharm Instrument is an old-fashioned machinery company, and Ruikang Pharmaceutical has entered into medical treatment. The circulation of equipment has only been a few years.

Ruikang Pharmaceutical was originally a single drug distribution enterprise , And the business is confined to the territory of Shandong Province. In recent years, the company has been in a strategic change, extending the drug distribution business to the field of medical device distribution, and expanding from the province of Shandong Province to the whole country.

In 2012, the company established a medical equipment sales team and established a provincial and a province-wide subsidiary hospital sales subsidiary. It began to enter the medical ring. In that year, the company achieved a total revenue of 4.622 billion yuan, of which the revenue of the equipment sector was 29 million yuan. Than 0.62%.

In 2013, the company's total revenue was 5.926 billion, of which equipment revenue was 236 million, an increase of 719.7% year-on-year.

In 2014, the company's total revenue was 7.786 billion, including equipment revenue of 540 million, an increase of 128.97%.

In 2015, the company's total revenue was 9.75 billion, of which equipment revenue was 1.051 billion, an increase of 94.66% year-on-year.

In 2016, the company's total revenue was 15.619 billion, including equipment revenue of 2.899 billion, an increase of 175.97%.

In 2017, the company's total revenue was 23.32 billion yuan, of which equipment revenue was about 7 billion yuan, and then it doubled.

By the end of 2017, Ruikang Pharmaceutical had completed the construction of platform companies in 31 provinces and built a national medical equipment distribution platform.

In just 6 years, Ruikang Pharmaceutical has achieved a market scale of 7 billion in less than 30 million in the market for medical device distribution. It has completed provinces across the country from a province in Shandong. Medical device distribution accounted for the total business volume of the company. The proportion is also less than 1% to 30%.

The medical device industry in China has been growing rapidly in recent years, and the medical device market continues to expand. This trend is expected to continue in the future. Even medical devices are considered to have more growth potential and higher profitability than drugs. Market development space is even greater.

Many traditional pharmaceutical companies have switched to or have extended their business to the field of medical devices, including both manufacturing and distribution companies. Ruikang Pharmaceutical is one of the representatives from the drug distribution business to medical device distribution.

What is special is that Ruikang Pharmaceuticals has made great strides in the field of medical devices.

The Ruikang Pharmaceutical Annual Report shows that the company’s foreign expansion policy is based on acquisitions of medical device companies, supplemented by the acquisition of pharmaceutical companies.

Among major traditional medicine companies, Ruikang Pharmaceuticals is a rare key betting on medical devices.

As of the first half of 2017, the company's direct sales of medicines outside the province covered 12 provinces across the country, and its medical equipment business covered nearly 30 provinces across the country. Medical devices preceded pharmaceuticals to complete the construction of the national platform.

In order to step out of Shandong and move toward the country, Ruikang Pharmaceutical has implemented many, many mergers and acquisitions in recent years. According to statistics, it included 186 pharmaceutical companies, equipment, inspections and other commercial companies in the next two years. Due to the generally small amount of M&A transactions, relevant information was not disclosed, and the industry did not report any major movements.

In addition, Ruikang Pharmaceuticals started with the direct sales model. Unlike distribution and fast-batch modes, direct selling is considered to be a model that matches the 'two-vote system' and does not hurt or benefit. The company’s inter-provincial copying is also a 'copy'. Medical institutions direct sales + medical equipment full product line service' business model.

In the future, if its expansion policy continues, the medical device segment is expected to share equal weight with the pharmaceutical sector, accounting for half of the company's revenue. Ruikang Pharmaceutical is also expected to become another national medical device circulation company in addition to the national drug device.

The medical device distribution industry is still low in concentration, and has not yet embraced a intensive reform and new policy like medicines. However, traditional large-scaled machinery companies represented by Sinopharm's equipment and traditional large-scale drug dealers represented by Ruikang Pharmaceutical have already acted. , Showed the great ambition to meet the industry changes, to reshuffle the industry in the 'unify the world'.

Industry reforms have not yet arrived and industry reforms have already begun. In the future market, who can stand out and stand on top of the pyramid?